Palvella Therapeutics Inc. Common Stock (PVLA)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as Graham would: first ask what is proven. Palvella is a 29-employee clinical-stage biopharma developing QTORIN rapamycin for rare skin diseases. The proven financial history is thin. In fiscal 2023, the year ended 2023-12-31, it reported revenue of $38.7M and net income of $18.7M, or $2.17 per diluted share. Since then, the filings show losses: in fiscal 2024, the year ended 2024-12-31, net loss was $17.4M and diluted EPS was -$7.83; in fiscal 2025, the year ended 2025-12-31, net loss was $41.7M and diluted EPS was -$3.71. The latest quarters worsened: in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $15.8M; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $21.9M. Revenue is not reported in those periods. Trailing free cash flow was -$36.5M, a -2.0% FCF yield as FairStock calculates it. Leverage is low with D/E 0.10, but Piotroski 1/9 signals weak fundamental momentum. At the 2026-10-13 close of $128.51, FairStock's P/B is 8.53 and P/E is -26.50; no earnings mean valuation rests on pipeline probabilities, not asset value. The Lynch category is TURNAROUND—loss in the latest year after earlier profits—but I see no durable moat yet: a single lead candidate in Phase 3 and Phase 2. Altman Z-Score 30.50, also a FairStock calculation, is not enough to offset cash burn and binary clinical risk. Price looks speculative, not cheap.

In plain English: Palvella Therapeutics is a small drug development company working on a topical gel for rare skin diseases. It has no recent revenue, is losing money, and its reported losses have been getting larger. At the 2026-10-13 closing price of $128.51, the stock looks expensive compared with the current business numbers, so it mainly reflects hopes for future drug approvals rather than today's profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer